Diplomat Announces 1st Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Diplomat Pharmacy (DPLO) Misses Q1 EPS by 26c, Revenues Beat; Offers FY19 EPS Views Below Consensus, FY19 Revenue Mid-Point Guidance Above Consensus
May 7, 2019 7:37 AM EDTDiplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of ($0.19), $0.26 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.17 billion.
First Quarter 2019 Highlights include:
Revenue of $1,257 million, compared to $1,342 millionSpecialty segment revenue of $1,168 million, compared to $1,153 millionPBM segment revenue of $98 million, compared to $191 millionSpecialty segment total prescriptions dispensed of 225,000, compared to 223,000PBM segment total volume, adjusted to... More